Modern medicine faces the formidable challenge of cancer because of its ability to evade immune surveillance and cultivate resistance to conventional therapies. Cancer cells, when overexpressed with CD47, send a “don’t eat me” signal to macrophages, successfully shielding them from immune destruction. Similarly, tyrosine kinase inhibitors (TKIs) have revolutionized cancer treatment by targeting oncogenic pathways, but their effectiveness is often compromised by resistance and minimal residual disease. This review explores a novel combination of CD47-SIRP-blockade and TKIs, addressing the limitations of monotherapies in cancer treatment. Disrupting the CD47-SIRP α interaction stimulates macrophage-mediated phagocytosis and revives exhausted T cells, while TKIs simultaneously target tumor growth drivers. Confirmation from preclinical studies indicates that this combination is capable of enhancing anti-tumor immunity and remodeling tumor microenvironments for enhanced therapeutic outcomes. However, hematotoxicity and tumor heterogeneity present challenges in the path to clinical translation. This review presents current findings, identifies key research areas, and proposes future directions to enhance this combinatorial approach. In the midst of a new era in cancer treatment, immune modulation combined with targeted therapies promises to offer more effective, less toxic, and personalized treatment options. This combination approach has the potential to significantly improve cancer treatment strategies by overcoming current therapeutic limitations.
KeywordsCD47Tyrosine Kinase InhibitorsCancer Immune EvasionTumor MicroenvironmentTargeted Cancer TherapyImmune Checkpoint Inhibitors
Ciriello, G., Magnani, L., Aitken, S.J., Akkari, L., Behjati, S., Hanahan, D., et al . (2023) Cancer Evolution: A Multifaceted Affair. Cancer Discovery , 14, 36-48. https://doi.org/10.1158/2159-8290.cd-23-0530
Barclay, A.N. and van den Berg, T.K. (2014) The Interaction between Signal Regulatory Protein Alpha (SIRP α ) and CD47: Structure, Function, and Therapeutic Target. Annual Review of Immunology , 32, 25-50. https://doi.org/10.1146/annurev-immunol-032713-120142
Josef, K., Jan, N., Jaroslav, M. and Oleksandr, N. (2013) Mathematical Model for Cancer Prevalence and Cancer Mortality. https://tvim.su/files/044-054%20Kalas%20Novotny%20Michalek%20Nakonechny.pdf
Lunt, N. (2023) The Global Challenge of Cancer Governance. World Medical & Health Policy , 15, 672-681. https://doi.org/10.1002/wmh3.577
Cabanos, H.F. and Hata, A.N. (2021) Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer. Cancers , 13, Article 2666. https://doi.org/10.3390/cancers13112666
Mancini, C., Lori, G., Pranzini, E. and Taddei, M.L. (2024) Metabolic Challengers Selecting Tumor-Persistent Cells. Trends in Endocrinology & Metabolism , 35, 263-276. https://doi.org/10.1016/j.tem.2023.11.005
Chuang, C., Zhen, Y., Ma, J., Lee, T., Hung, H., Wu, C., et al . (2024) CD47-Mediated Immune Evasion in Early-Stage Lung Cancer Progression. Biochemical and Biophysical Research Communications , 720, Article ID: 150066. https://doi.org/10.1016/j.bbrc.2024.150066
Polara, R., Ganesan, R., Pitson, S.M. and Robinson, N. (2024) Cell Autonomous Functions of CD47 in Regulating Cellular Plasticity and Metabolic Plasticity. Cell Death & Differentiation , 31, 1255-1266. https://doi.org/10.1038/s41418-024-01347-w
Abd alkareem, F.O. and Mohamad, B.J. (2024) Immunohistochemical Expression and Histopathological Role of CD47 in Colorectal Cancer in Iraqi Patients. Journal of the Faculty of Medicine Baghdad , 66, 122-128. https://doi.org/10.32007/jfacmedbagdad.6622275
Xing, L., Wang, Z., Feng, Y., Luo, H., Dai, G., Sang, L., et al . (2024) The Biological Roles of CD47 in Ovarian Cancer Progression. Cancer Immunology , Immunotherapy , 73, Article No. 145. https://doi.org/10.1007/s00262-024-03708-3
Wu, F., Pang, H., Li, F., Hua, M., Song, C. and Tang, J. (2024) Progress in Cancer Research on the Regulator of Phagocytosis CD47, Which Determines the Fate of Tumor Cells (Review). Oncology Letters , 27, Article No. 256. https://doi.org/10.3892/ol.2024.14389
Yang, Y., Wu, H., Yang, Y., Kang, Y., He, R., Zhou, B., et al . (2023) Dual Blockade of CD47 and CD24 Signaling Using a Novel Bispecific Antibody Fusion Protein Enhances Macrophage Immunotherapy. Molecular Therapy — Oncolytics , 31, Article ID: 100747. https://doi.org/10.1016/j.omto.2023.100747
Sue, M., Tsubaki, T., Ishimoto, Y., Hayashi, S., Ishida, S., Otsuka, T., et al . (2024) Blockade of SIRP α -Cd47 Axis by Anti-SIRP α Antibody Enhances Anti-Tumor Activity of DXd Antibody-Drug Conjugates. PLOS ONE , 19, e0304985. https://doi.org/10.1371/journal.pone.0304985
Hussain, S., Mursal, M., Verma, G., Hasan, S.M. and Khan, M.F. (2024) Targeting Oncogenic Kinases: Insights on FDA Approved Tyrosine Kinase Inhibitors. European Journal of Pharmacology , 970, Article ID: 176484. https://doi.org/10.1016/j.ejphar.2024.176484
Li, J., Gong, C., Zhou, H., Liu, J., Xia, X., Ha, W., et al . (2024) Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives. Intern ational Journal of Molecular Sciences , 25, Article No. 5489. https://doi.org/10.3390/ijms25105489
Jie, X.-L., Kong, Y.-Y. and Zhou, G.-B. (2023) Latest Findings on the Role of CD47 in Tumor Immune Evasion and Related Targeted Therapies. Journal of Sichuan Univ ersity . Medical Science Edition , 54, 455-461.
Hu, L., Zhuang, W., Chen, M., Liao, J., Wu, D., Zhang, Y., et al . (2024) EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion through Up-Regulation of CD47. Journal of Thoracic Oncology , 19, 1186-1200. https://doi.org/10.1016/j.jtho.2024.03.019
Liang, H., Zheng, Y., Huang, Z., Dai, J., Yao, L., Xie, D., et al . (2024) Pan-Cancer Analysis for the Prognostic and Immunological Role of CD47: Interact with TNFRSF9 Inducing CD8+ T Cell Exhaustion. Discover Oncology , 15, Article No. 149. https://doi.org/10.1007/s12672-024-00951-z
Liu, Y., Weng, L., Wang, Y., Zhang, J., Wu, Q., Zhao, P., et al . (2024) Deciphering the Role of CD47 in Cancer Immunotherapy. Journal of Advanced Research , 63, 129-158. https://doi.org/10.1016/j.jare.2023.10.009
Huang, K., Liu, Y., Wen, S., Zhao, Y., Ding, H., Liu, H., et al . (2023) Binding Mechanism of CD47 with SIRP α Variants and Its Antibody: Elucidated by Molecular Dynamics Simulations. Molecules , 28, Article No. 4610. https://doi.org/10.3390/molecules28124610
Morrissey, M.A., Kern, N. and Vale, R.D. (2020) CD47 Ligation Repositions the Inhibitory Receptor SIRPA to Suppress Integrin Activation and Phagocytosis. Immunity , 53, 290-302.e6. https://doi.org/10.1016/j.immuni.2020.07.008
Wang, J., Tseng, C., Teng, H., Kuo, P., Cheng, Y., Chen, Y., et al . (2022) 496 HCB101: A Safe and Effective Ligand Trap Therapeutic Targeting the CD47-SIRP α Signaling Pathway for Cancer Treatment. Journal for ImmunoTherapy of Cancer , 10, A517.
Wang, B., Pan, L., Chen, M., Ma, Y., Gao, J., Tang, D., et al . (2023) SIRP-Alpha-IL-6 Axis Induces Immunosuppressive Macrophages in Non-Small-Cell Lung Cancer. Biochemical and Biophysical Research Communications , 682, 386-396. https://doi.org/10.1016/j.bbrc.2023.10.035
Chen, W., Li, X., Wang, J., Song, N., Zhu, A. and Jia, L. (2019) miR-378a Modulates Macrophage Phagocytosis and Differentiation through Targeting CD47-SIRP α Axis in Atherosclerosis. Scandinavian Journal of Immunology , 90, e12766. https://doi.org/10.1111/sji.12766
Gajendran, N., Hernandez, M.G., Yende, A., Alahmadi, Z., Li, X., Munoz, Z., et al . (2023) Abstract 666: Targeting the CD47/SIRP α “Do Not Eat Me” Phagocytic Pathway in Macrophages to Improve Anti-CD47 Immune Therapy. Cancer Research , 83, 666-666. https://doi.org/10.1158/1538-7445.am2023-666
Wang, Q.Q., et al . (2023) Evaluation of CD47 in the Suppressive Tumor Microenvironment and Immunotherapy in Prostate Cancer. Journal of Immunology Research , 2023, Article ID: 2473075.
Zimarino, C., Moody, W., Davidson, S.E., Munir, H. and Shields, J.D. (2024) Disruption of CD47-SIRP α Signaling Restores Inflammatory Function in Tumor-Associated Myeloid-Derived Suppressor Cells. iScience , 27, Article ID: 109546. https://doi.org/10.1016/j.isci.2024.109546
Biedermann, A., Patra-Kneuer, M., Mougiakakos, D., Büttner-Herold, M., Mangelberger-Eberl, D., Berges, J., et al . (2024) Blockade of the CD47/SIRP α Checkpoint Axis Potentiates the Macrophage-Mediated Anti-Tumor Efficacy of Tafasitamab. Haematologi ca , 109, 3928-3940. https://doi.org/10.3324/haematol.2023.284795
Lim, H.Y., Ahn, J.S., Park, J.O., Yong Hong, J., Seon, H., Lee, J.K., et al . (2023) 1035P Phase I Dose Escalation Study of IMC-002, a Novel Anti-Cd47 Monoclonal Antibody, in Patients with Advanced Solid Tumors. Annals of Oncology , 34, S629. https://doi.org/10.1016/j.annonc.2023.09.2174
Zhang, Q., Liu, A., Shi, J., Cai, Q., Qu, Z., Liu, S., et al . (2023) A First-in-Human Study of MIL95, an Anti-CD47 Monoclonal Antibody (mAb), in Patients with Advanced Solid Tumors and Lymphomas. Journal of Clinical Oncology , 41, e14513. https://doi.org/10.1200/jco.2023.41.16_suppl.e14513
Osorio, J.C., Smith, P., Knorr, D.A. and Ravetch, J.V. (2023) The Antitumor Activities of Anti-CD47 Antibodies Require Fc-Fc γ R Interactions. Cancer Cell , 41, 2051-2065.e6. https://doi.org/10.1016/j.ccell.2023.10.007
Li, Y., Liu, J., Chen, W., Wang, W., Yang, F., Liu, X., et al . (2023) A pH-Dependent Anti-CD47 Antibody That Selectively Targets Solid Tumors and Improves Therapeutic Efficacy and Safety. Journal of Hematology & Oncology , 16, Article No. 2. https://doi.org/10.1186/s13045-023-01399-4
Tian, W., Li, S., Chen, D., Yang, Y., Guo, H., Liu, D., et al . (2024) Abstract LB129: Preclinical Development of a Bispecific Antibody-Trap Selectively Targeting CD38 and CD47 for Treating Hematologic Malignancies. Cancer Research , 84, LB129. https://doi.org/10.1158/1538-7445.am2024-lb129
Baek, B.S., Kim, M.G., Kim, J.H., Jang, I.Y., Kim, S.M., Kim, J.H., et al . (2024) Abstract 2719: Papiliximab, a Bispecific Nanobody Targeting CD47 and PDL1 Retards Tumor Growth without Hemolysis. Cancer Research , 84, 2719-2719. https://doi.org/10.1158/1538-7445.am2024-2719
Zhang, K., Xu, Y., Chang, X., Xu, C., Xue, W., Ding, D., et al . (2024) Co-Targeting CD47 and VEGF Elicited Potent Anti-Tumor Effects in Gastric Cancer. Cancer Immunolo gy , Immunotherapy , 73, Article No. 75. https://doi.org/10.1007/s00262-024-03667-9
Combarel, D., Dousset, L., Bouchet, S., Ferrer, F., Tetu, P., Lebbe, C., et al . (2024) Tyrosine Kinase Inhibitors in Cancers: Treatment Optimization—Part I. Critical Rev iews in Oncology/Hematology , 199, Article ID: 104384. https://doi.org/10.1016/j.critrevonc.2024.104384
Ferrer, F., Tetu, P., Dousset, L., Lebbe, C., Ciccolini, J., Combarel, D., et al . (2024) Tyrosine Kinase Inhibitors in Cancers: Treatment Optimization—Part II. Critical Rev iews in Oncology/Hematology , 200, Article ID: 104385. https://doi.org/10.1016/j.critrevonc.2024.104385
Costa, A., Abruzzese, E., Latagliata, R., Mulas, O., Carmosino, I., Scalzulli, E., et al . (2024) Safety and Efficacy of TKIs in Very Elderly Patients (≥75 Years) with Chronic Myeloid Leukemia. Journal of Clinical Medicine , 13, Article No. 273. https://doi.org/10.3390/jcm13010273
Zhang, X.S, Liu, B.C., Huang, J., et al . (2024) A Predictive Model for Therapy Failure in Chronic Myeloid Leukemia Patients Receiving Tyro-Sine Kinase Inhibitor Therapy. Blood , 144, 1951-1961.
Jeong, S.U., Park, J., Yoon, S.Y., Hwang, H.S., Go, H., Shin, D., et al . (2024) Ifitm3-Mediated Activation of TRAF6/MAPK/AP-1 Pathways Induces Acquired TKI Resistance in Clear Cell Renal Cell Carcinoma. Investigative and Clinical Urology , 65, 84-93. https://doi.org/10.4111/icu.20230294
Wang, Q., Yang, S., Wang, K. and Sun, S. (2019) MET Inhibitors for Targeted Therapy of EGFR TKI-Resistant Lung Cancer. Journal of Hematology & Oncology , 12, Article No. 63. https://doi.org/10.1186/s13045-019-0759-9
Stone, L. (2017) Targeted Therapies: Reversal of Fortunes for TKI Resistance. Nature Reviews Clinical Oncology , 14, 263-263. https://doi.org/10.1038/nrclinonc.2017.33
Park, H., Kim, S., Keam, B., Chung, H., Seok, S.H., Kim, S., et al . (2022) Blockade of CD47 Enhances the Antitumor Effect of Macrophages in Renal Cell Carcinoma through Trogocytosis. Scientific Reports , 12, Article No. 12546. https://doi.org/10.1038/s41598-022-16766-3
Li, B., Hao, Y., He, H., Fan, Y., Ren, B., Peng, X., et al . (2024) CD47-SIRP α Blockade Sensitizes Head and Neck Squamous Cell Carcinoma to Cetuximab by Enhancing Macrophage Adhesion to Cancer Cells. Cancer Research , 84, 3189-3206. https://doi.org/10.1158/0008-5472.can-24-0176
Nishiga, Y., Drainas, A.P., Baron, M., Bhattacharya, D., Barkal, A.A., Ahrari, Y., et al . (2022) Radiotherapy in Combination with CD47 Blockade Elicits a Macrophage-Mediated Abscopal Effect. Nature Cancer , 3, 1351-1366. https://doi.org/10.1038/s43018-022-00456-0
Tang, L., Yin, Y., Cao, Y., Fu, C., Liu, H., Feng, J., et al . (2023) Extracellular Vesicles‐derived Hybrid Nanoplatforms for Amplified CD47 Blockade‐Based Cancer Immunotherapy. Advanced Materials , 35, e2303835. https://doi.org/10.1002/adma.202303835
Shen, Y., Ji, M., Yi, H., Shen, R., Fu, D., Cheng, S., et al . (2024) CD47 Overexpression Is Related to Tumour‐Associated Macrophage Infiltration and Diffuse Large B-Cell Lymphoma Progression. Clinical and Translational Medicine , 14, e1532. https://doi.org/10.1002/ctm2.1532
Boardman, A.P., James, S. and Van Den Brink, M.R.M. (2023) Targeting CD47 in Lymphoid Malignancies with CAR T Cells. Journal of Clinical Oncology , 41, 2513-2513. https://doi.org/10.1200/jco.2023.41.16_suppl.2513
Masroni, M.S.b., Leong, S.M., Cheng, H., Lim, G.S., Heng, N.Z.Y., Law, C.T., et al . (2023) miR‐101‐5p Modulation of CD47 in Diffuse Large B‐Cell Lymphoma: Implications for Anti‐CD47 Immunotherapy and Prognostication. British Journal of Haematology , 204, 730-734. https://doi.org/10.1111/bjh.19264
Jiang, C., Sun, H., Jiang, Z., Tian, W., Cang, S. and Yu, J. (2024) Targeting the CD47/SIRP α Pathway in Malignancies: Recent Progress, Difficulties and Future Perspectives. Frontiers in Oncology , 14, Article ID: 1378647. https://doi.org/10.3389/fonc.2024.1378647
Chen, Y., Shi, W., Shi, J. and Lu, J. (2021) Progress of CD47 Immune Checkpoint Blockade Agents in Anticancer Therapy: A Hematotoxic Perspective. Journal of Cancer Research and Clinical Oncology , 148, 1-14. https://doi.org/10.1007/s00432-021-03815-z
Fu, Z., Feng, M., Wu, J., Liu, B., Fu, J. and Song, W. (2024) Photodynamic Therapy Synergizes CD47 Blockade Strategy for Enhanced Antitumor Therapy. Molecular Pharm aceutics , 21, 3897-3908. https://doi.org/10.1021/acs.molpharmaceut.4c00254
Hilinski, G., Stearns, B., Vibhute, S., Hughes, T., Tridandapani, S., Johnstone, M.E., et al . (2023) The Potent Dihydroorotate Dehydrogenase Inhibitor, Hosu-53, Exhibits Compelling Monotherapy Efficacy in Multiple Myeloma and Augments CD47 Targeted Therapy. Blood , 142, 4692-4692. https://doi.org/10.1182/blood-2023-189238
Creeden, J.F., Sevier, J., Zhang, J., Lapitsky, Y., Brunicardi, F.C., Jin, G., et al . (2024) Smart Exosomes Enhance PDAC Targeted Therapy. Journal of Controlled Release , 368, 413-429. https://doi.org/10.1016/j.jconrel.2024.02.037
Wang, T., Wang, S., Du, Y., Sun, D., Liu, C., Liu, S., et al . (2024) Gentulizumab, a Novel Anti-Cd47 Antibody with Potent Antitumor Activity and Demonstrates a Favorable Safety Profile. Journal of Translational Medicine , 22, Article No. 220. https://doi.org/10.1186/s12967-023-04710-6
Puro, R.J., Bouchlaka, M.N., Hiebsch, R.R., Capoccia, B.J., Donio, M.J., Manning, P.T., et al . (2020) Development of AO-176, a Next-Generation Humanized Anti-Cd47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding. Molecular Cancer Therapeutics , 19, 835-846. https://doi.org/10.1158/1535-7163.mct-19-1079
Zhuang, Z., Zhou, J., Qiu, M., Li, J., Lin, Z., Yi, H., et al . (2024) The Combination of Anti-CD47 Antibody with CTLA4 Blockade Enhances Anti-Tumor Immunity in Non-Small Cell Lung Cancer via Normalization of Tumor Vasculature and Reprogramming of the Immune Microenvironment. Cancers , 16, Article No. 832. https://doi.org/10.3390/cancers16040832
Lau, A.P.Y., Khavkine Binstock, S.S. and Thu, K.L. (2023) CD47: The Next Frontier in Immune Checkpoint Blockade for Non-Small Cell Lung Cancer. Cancers , 15, Article No. 5229. https://doi.org/10.3390/cancers15215229
Du, L., Su, Z., Wang, S., Meng, Y., Xiao, F., Xu, D., et al . (2023) EGFR‐Induced and C‐SRC‐Mediated CD47 Phosphorylation Inhibits Trim21‐Dependent Polyubiquitylation and Degradation of CD47 to Promote Tumor Immune Evasion. Advanced Scie nce , 10, Article ID: 2206380. https://doi.org/10.1002/advs.202206380
Wang, C., Feng, Y., Patel, D., Xie, H., Lv, Y. and Zhao, H. (2023) The Role of CD47 in Non-Neoplastic Diseases. Heliyon , 9, e22905. https://doi.org/10.1016/j.heliyon.2023.e22905
Zhou, H., Wang, W., Xu, H., Liang, Y., Ding, J., Lv, M., et al . (2024) Metabolic Reprograming Mediated by Tumor Cell-Intrinsic Type I IFN Signaling Is Required for CD47-SIRP α Blockade Efficacy. Nature Communications , 15, Article No. 5759. https://doi.org/10.1038/s41467-024-50136-z
Jin, S., Wang, H., Li, Y., Yang, J., Li, B., Shi, P., et al . (2024) Discovery of a Novel Small Molecule as CD47/SIRP α and PD-1/PD-L1 Dual Inhibitor for Cancer Immunotherapy. Cell Communication and Signaling , 22, Article No. 173. https://doi.org/10.1186/s12964-024-01555-4